Your Data Moves Research Forward — The Registry’s Immunotherapy Survey Data is Presented

This month we are excited to announce that a summary of interim data was submitted and accepted as a poster for the Society for Immunotherapy of Cancer 33rd Annual Conference, held on November 7-11th, 2018. If you participated in our Immunotherapy Questionnaire, your anonymous data has directly impacted medical research - thank you! Read more about our study and its findings here.

This month we are excited to announce that a summary of interim data was submitted and accepted as a poster for the Society for Immunotherapy of Cancer 33rd Annual Conference, held on November 7-11th, 2018. If you participated in our Immunotherapy Questionnaire, your anonymous data has directly impacted medical research - thank you! Read more about our study and its findings here.

Background |Our study is looking into immunotherapy treatments from the perspective of the patient. Patient-reported outcomes (PROs) are gaining interest in the medical research community as they provide information complementary to provider-rated adverse events. While several studies have been published on PROs in lung cancer patients receiving immune checkpoint inhibitors, all have been part of a clinical trial. This study is among the first to evaluate patient-reported toxicities of immune checkpoint inhibitors outside the context of a clinical trial.

The goal | This interim analysis aims to describe patient-reported toxicities and quality of life outside the context of a clinical trial in lung cancer patients treated with immune checkpoint inhibitors. Results so far indicate that patient-reported toxicities of immune checkpoint inhibitors are common in lung cancer patients.

Looking to the future | When the study wraps up at the end of next year, the study will result in a better understanding of common patient-reported toxicities in patients receiving immunotherapy. We hope the study will validate a PRO questionnaire for patients treated with immunotherapy and provide a measure that will be ready to use in future clinical trials and other research on immunotherapy.

Learn more about the Society for Immunotherapy of Cancer 33rd Annual Conference and what all went on! To read the full summary of our study, click here (then go to page 828, item P630).

If you are on immunotherapy and have not yet taken our Immunotherapy Questionnaire, log in today and answer a few questions about your treatment journey.

Together we can make a difference as we continue the fight to end lung cancer.

Sandra Shaw
Director, Patient Registry
Bonnie J. Addario Lung Cancer Foundation
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.lungcancerregistry.org